France· FR:68093737
ZYDELIG 150 mg, comprimé pelliculé
A medicinal product containing idélalisib, registered in France by GILEAD SCIENCES IRELAND UC (IRLANDE), on the national reimbursement list.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- IDÉLALISIB
- Manufacturer
- GILEAD SCIENCES IRELAND UC (IRLANDE)
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- cip1334009279597211 flacon(s) polyéthylène haute densité (PEHD) avec fermeture de sécurité enfant de 60 comprimé(s)EUR 3.36
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Idélalisib in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesZydeligGilead Sciences, Inc.
- SwitzerlandZydelig 150 mg, FilmtablettenGilead Sciences Switzerland Sàrl
- CzechiaZYDELIGGilead Sciences Ireland UC, Carrigtohill
- SpainZydelig 150 mg comprimidos recubiertos con peliculaGilead Sciences Ireland Unlimited Company
- FinlandZydeligGilead Sciences Ireland UC
- BelgiumZydelig 150 mgGilead Sciences Ireland UC
- IcelandZydeligGilead Sciences Ireland UC*
- NetherlandsZydelig 150 mg, filmomhulde tabletGilead Sciences Ireland UC
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Zydelig
- Liechtenstein · Zydelig
- Norway · Zydelig
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f3d5e87a-528b-4b3f-bc73-89155f94fa55 GET /v1/drugs/f3d5e87a-528b-4b3f-bc73-89155f94fa55?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "68093737",
"date_amm": "2014-09-18",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/14/938",
"substance": "IDÉLALISIB",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "comprimé pelliculé",
"voies_administration": "orale",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about idélalisib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.